Methotrexate products: information for supporting intrathecal risk assessment

John Minshull, Deputy Director, London Medicines Information Service, Specialist Pharmacy ServicePublished

Methotrexate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Licensed for intrathecal use

Products licensed for intrathecal use are the first line option and should be used wherever suitable.

Accord

Strength

25 mg/mL 2mL, 10mL, 20mL or 40mL vials

Hospira

Strength

2.5 mg/mL in 2mL vials
25 mg/mL 2mL, 10mL, 20mL or 40mL vials

Not licensed for intrathecal use, limited information available

Products with partial information that are not licensed for intrathecal administration can still sometimes be used. Refer to the advice in our article and complete a risk assessment to enable you to interpret the details below and choose an appropriate product.

Hospira

Strength

100 mg/mL 10mL or 50mL vials

Excipients

Sodium hydroxide, water for injection

Osmolarity

No information

pH

No information

Endotoxin content

No information

Medac

Strength

100 mg/mL 10mL or 50mL vials

Excipients

Sodium hydroxide (pH adjustment), water for injection

Osmolarity

No information

pH

No information

Endotoxin content

No information

All our intrathecal product resources

Understand what to consider when giving medicines via the intrathecal route and use our material to help inform your risk assessment

Learn more about us or ask for help

Learn more about us, how we're supporting the COVID-19 vaccination programme, and our transformation journey.
If you're a healthcare professional who needs further advice, get in touch with us. We answer questions about Medicines Optimisation issues, including those about the COVID-19 vaccination programme. Help us to help you: tell us where on our site you were.